MONTREAL, April 15, 2021 /CNW/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of evidence-based botanical products for the
healthcare industry, is pleased to announce the launch of Awaye™
pain relief cream for the Canadian market. Awaye™ provides a new
generation of relief from acute and chronic pain by
exploiting the CB2 receptors of the endocannabinoid system,
the body's built in pain and inflammation defense
system. Awaye™ is a unique Health Canada approved topical
cream that provides relief from pain through
complimentary mechanisms of action not found in any other product
currently available on the market.
![Lumiera Health Inc. (CNW Group/Lumiera Health Inc.) Lumiera Health Inc. (CNW Group/Lumiera Health Inc.)](https://mma.prnewswire.com/media/1488322/Lumiera_Health_Inc__Lumiera_Health_begins_sales_of_Awaye__pain_r.jpg)
Along with this new product line, the Company also wishes to
announce that, as part of its commitment to invest in its digital
platforms, it is launching a new e-commerce website to support the
sale of Awaye™. The Brand will also be launched in select
pharmacies across Quebec before
expanding to other markets.
"This important milestone clearly demonstrates Lumiera's
capacity to bring innovative health products from concept to market
and shows our commitment to making e-commerce an important part of
our revenue stream. We are excited to see this launch as a
continuation of our plan to expand our portfolio and grow revenue
through both offline and online sales channels," says Carlos Ponce, CEO of Lumiera.
For more information about Awaye™ products,
visit www.awaye.ca
About Lumiera Health Inc.
Lumiera specializes in the development and commercialization of
evidence-based botanical products for the healthcare industry. The
Company sells both oral and topical botanical agents to help manage
unmet medical needs through its Holizen Laboratories division.
Lumiera is also developing and commercializing a unique portfolio
of products acting on the endocannabinoid system and providing
innovative solutions for chronic pain and inflammation. The Company
is a pioneer in the health and pain management innovation space and
the Lumiera brand is rooted in the core brand values of science,
nature and compassion. Passionate about making people feel
better, we deliver trustworthy and scientifically proven solutions
that work with the body's own system.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2019,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.